126 related articles for article (PubMed ID: 9260734)
1. Methylene blue adjuvant therapy of schizophrenia.
Deutsch SI; Rosse RB; Schwartz BL; Fay-McCarthy M; Rosenberg PB; Fearing K
Clin Neuropharmacol; 1997 Aug; 20(4):357-63. PubMed ID: 9260734
[TBL] [Abstract][Full Text] [Related]
2. Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis.
Farina Junior JA; Celotto AC; da Silva MF; Evora PR
Med Sci Monit; 2012 May; 18(5):HY13-7. PubMed ID: 22534716
[TBL] [Abstract][Full Text] [Related]
3. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.
Rosse RB; Kendrick K; Fay-McCarthy M; Prell GD; Rosenberg P; Tsui LC; Wyatt RJ; Deutsch SI
Clin Neuropharmacol; 1996 Aug; 19(4):341-8. PubMed ID: 8828997
[TBL] [Abstract][Full Text] [Related]
4. Halothane attenuates nitric oxide relaxation of rat aortas by competition for the nitric oxide receptor site on soluble guanylyl cyclase.
Jing M; Ling GS; Bina S; Hart JL; Muldoon SM
Eur J Pharmacol; 1998 Jan; 342(2-3):217-24. PubMed ID: 9548389
[TBL] [Abstract][Full Text] [Related]
5. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
7. The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target.
Evora PR; Viaro F
Curr Drug Targets; 2006 Sep; 7(9):1195-204. PubMed ID: 17017895
[TBL] [Abstract][Full Text] [Related]
8. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
9. The effects of galantamine on psychopathology in chronic stable schizophrenia.
Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
[TBL] [Abstract][Full Text] [Related]
10. Methylene blue, a soluble guanylyl cyclase inhibitor, reduces the sevoflurane minimum alveolar anesthetic concentration and decreases the brain cyclic guanosine monophosphate content in rats.
Masaki E; Kondo I
Anesth Analg; 1999 Aug; 89(2):484-9. PubMed ID: 10439772
[TBL] [Abstract][Full Text] [Related]
11. Methylene blue and cirrhosis: pathophysiologic insights, therapeutic dilemmas.
Fallon MB
Ann Intern Med; 2000 Nov; 133(9):738-40. PubMed ID: 11074907
[No Abstract] [Full Text] [Related]
12. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
Borison RL; Arvanitis LA; Miller BG
J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
14. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.
Rosse RB; Fay-McCarthy M; Kendrick K; Davis RE; Deutsch SI
Clin Neuropharmacol; 1996 Oct; 19(5):444-50. PubMed ID: 8889288
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic effect of methylene blue microinjected into the dorsal periaqueductal gray matter.
de-Oliveira RW; Guimarães FS
Braz J Med Biol Res; 1999 Dec; 32(12):1529-32. PubMed ID: 10585635
[TBL] [Abstract][Full Text] [Related]
16. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
18. The effects of clozapine on symptom clusters in treatment-refractory patients.
Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC
J Clin Psychopharmacol; 1997 Feb; 17(1):49-53. PubMed ID: 9004057
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
